Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection.

ABSTRACT:

Background

Treatment in bipolar disorder (BD) is commonly applied as a multimodal therapy based on decision algorithms that lack an integrative understanding of molecular mechanisms or a biomarker associated clinical outcome measure. Pharmacogenetics/genomics study the individual genetic variation associated with drug response. This selective review of pharmacogenomics and pharmacogenomic testing (PGT) in BD will focus on candidate genes and genome wide association studies of pharmacokinetic drug metabolism and pharmacodynamic drug response/adverse event, and the potential role of decision support tools that incorporate multiple genotype/phenotype drug recommendations.

Main body

We searched PubMed from January 2013 to May 2019, to identify studies reporting on BD and pharmac

SUBMITTER: Cuellar-Barboza AB 

PROVIDER: S-EPMC7338319 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature